Therapeutic Approaches in Patients with Inflammatory Myopathies

ABSTRACT

Among the group of inflammatory myopathies, dermatomyositis (DM) remains the most treatable subset responding, in the majority of the cases, to steroids, intravenous immunoglobulin (IVIg), or immunosuppressants. Inclusion-body myositis (IBM) remains the most difficult disease to treat; in uncontrolled studies immunosuppressants and steroids have not helped, and controlled trials with IVIg have been disappointing. Polymyositis (PM) is a very uncommon, although still overdiagnosed, disorder and its rarity poses difficulties in performing large-scale therapeutic studies; based on small series, however, PM seems to variably respond to immunotherapeutic interventions. The most consistent problem in the treatment of inflammatory myopathies remains the distinction of true PM from the difficult-to-treat cases of IBM, or from necrotizing myopathies and dystrophic processes where secondary endomysial inflammation may be prominent. The future in the management of PM, DM, and IBM seems promising because of the availability of new agents directed at T-cell activation molecules, cytokines, chemokines, and adhesion receptors. In IBM, the use of such immunomodulatory drugs may be combined with agents that block cytokine-enhancing amyloid or with agents that inhibit the formation and polymerization of amyloid fibrils.

KEYWORDS

Polymyositis - dermatomyositis - inclusion-body myositis

REFERENCES

• 1 Dalakas M C. Polymyositis, dermatomyositis and inclusion body myositis.  N Engl J Med . 1991;  325 1487-1498
• 2 Dalakas M C, Karpati G. The inflammatory myopathies. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of Voluntary Muscle 7th ed. Cambridge: Cambridge University Press 2001: 636-659
• 3 Mendell J R, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis.  Arch Neurol . 1991;  48 1229-1234
• 4 Askanas V, Serdaroglu P, Engel W K, Alvarez R B. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis.  Neurology . 1992;  42 460-461
• 5 Dalakas M C, Hohlfeld R. Polymyositis and dermatomyositis (in press).  Lancet.
• 6 Dalakas M C. Immunopathogenesis of inflammatory myopathies.  Ann Neurol . 1995;  37 74-86
• 7 Dalakas M C. The molecular and cellular pathology of inflammatory muscle diseases.  Curr Opin Pharmacol . 2001;  1 300-306
• 8 Dalakas M C. Progress in inflammatory myopathies: good but not good enough [editorial].  J Neurol Neurosurg Psychiatry . 2001;  70 569-573
• 9 Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R. T cell receptor in polymyositis: clonal expression of autoaggressive CD8+T cells.  J Exp Med . 1995;  181 1863-1868
• 10 Amemiya K, Granger R P, Dalakas M C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies.  Brain . 2000;  123 2030-2039
• 11 Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions.  J Immunol . 1998;  161 5943-5951
• 12 Murata K, Dalakas M C. Expression of the co-stimulatory molecule BB-1, the ligand CTLA-4 and CD28, and their mRNA in inflammatory myopathies.  Am J Pathol . 1999;  155 453-460
• 13 Dalakas M C. Current treatment of inflammatory myopathies.  Curr Opin Rheumatol . 1994;  6 595-601
• 14 Dalakas M C. The treatment of polymyositis, dermatomyositis and Inclusion body myositis. In: Johnson RT, Griffin JW, eds. Current Therapy in Neurology St. Louis: Mosby Year Book 1996: 407-412
• 15 Mowzoon N, Sussman A, Bradley W G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.  J Neurol Sci . 2001;  185 119-122
• 16 Miller F W, Leitman S F, Cronin M E. et al . Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis.  N Engl J Med . 1992;  326 1380-1384
• 17 Dalakas M C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.  Muscle Nerve . 1999;  22 1479-1497
• 18 Dalakas M C, Illa I, Dambrosia J M. et al . A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis.  N Engl J Med . 1993;  329 1993-2000
• 19 Dalakas M C, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study.  Neurology . 1997;  48 712-716
• 20 Dalakas M C, Koffman B M, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.  Neurology . 2001;  56 323-327
• 21 Walter M C, Lochmuller H, Toepfer M. et al . High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.  J Neurol . 2000;  247 22-28
• 22 Cherin P, Pelletier S, Teixeira A. et al . Intravenous immunoglobulin for dysphagia of inclusion body myositis.  Neurology . 2002;  58 326
• 23 Peterson E J, Koretzky G A. Signal transduction in T lymphocytes.  Clin Exp Rheumatol . 1999;  17 107-114
• 24 Gold R, Dalakas M C, Toyka K V. Immunotherapy in autoimmune neuromuscular disorders.  Lancet Neurology . 2003;  2 22-32
• 25 Hohlfeld R, Dalakas M C. Basic principles of immunotherapy for neurologic diseases.  Semin Neurol . 2003;  23 121-132
• 26 Dalakas M C. How to diagnose and treat the inflammatory myopathies.  Sem Neurol . 1994;  14 137-145
• 27 Bohan A, Peter J B. Polymyositis and dermatomyositis (first of two parts).  N Engl J Med . 1975;  292 344-347
• 28 Mastaglia F L. Treatment of autoimmune inflammatory myopathies.  Curr Opin Neurol . 2000;  13 507-509